Category Earnings Results

Dabur India Ltd
Dabur India Ltd: Buy Target at ₹597. Hits 52-Week Low Amid Market Decline & Growth Concerns

Business and Industry Overview: 

Dabur is a well-known Indian company that makes natural and Ayurvedic products. It sells products in over 120 countries, including Asia, Europe, and the U.S. Some of its popular brands are Dabur Chyawanprash, Dabur Honey, Dabur Red Paste, Dabur Amla, Vatika, and Real fruit juices. The company started in 1884 as a small business making Ayurvedic medicines in Kolkata. Today, it is a large global company offering products in healthcare, personal care, home care, and food & beverages. Dabur mixes traditional Ayurvedic knowledge with modern science to create good-quality products. It has grown from a family business into a professionally managed company while maintaining strong values and innovation.   

Dabur also cares about nature and the environment. It works to protect rare plants used in Ayurvedic medicines. The company helps farmers grow these plants. Dabur has set up greenhouses in India and Nepal to provide free saplings to farmers. This helps farmers earn money while also saving nature. The company also trains tribal communities and small farmers in eco-friendly farming. Through these efforts, Dabur is growing its business while also helping people and the environment. 

CRISIL forecasts 7-9% revenue growth for the FMCG sector in the current FY25, driven by increased volume and rural demand recovery. The Fast-moving consumer Goods (FMCG) sector is India’s fourth-largest sector and has been expanding at a healthy rate over the years because of rising disposable income, a rising youth population, and rising brand awareness among consumers. With household and personal care products accounting for 50% of FMCG sales in India, the industry is an important contributor to India’s GDP. And Dabour has 17.2% market share in the industry. 

Dabur India Limited, a leading Ayurvedic and FMCG company, has grown significantly since its founding in 1884. It started with Ayurvedic medicines and expanded into personal care, food, and healthcare products. Over the years, Dabur launched new products like baby care, personal hygiene, and energy drinks while also expanding its reach through acquisitions like Badshah Masala. The company has made key investments, such as setting up new manufacturing plants, including an all-women production line. Dabur is also focused on sustainability, achieving plastic waste neutrality, and adding electric vehicles to its supply chain. It continues to grow its business globally while staying committed to environmental and social responsibility. 

Latest Stock News: 

Dabur India Ltd.’s stock price has been falling and has now reached its lowest point in the past year. The company’s stock is performing poorly and is below key market levels, similar to the overall market trend. Although Dabur has a strong return on equity, its long-term growth does not seem very promising. 

The entire FMCG (fast-moving consumer goods) sector is facing difficulties. On Tuesday, the FMCG index, which tracks major companies in this industry, dropped to its lowest level in nearly two years due to weak demand and rising costs. In the last month alone, this index fell by 12%, while the broader market (Sensex) dropped by 7%. Over six months, FMCG stocks have fallen by 22%, mainly due to low earnings, slow demand, and inflation. 

Urban demand is weak due to job losses and slow salary growth, while rural areas have recovered due to good monsoons and government support. The sector recorded only 2-4% sales volume growth in the December 2024 quarter, with urban demand falling for three straight quarters. Rising raw material costs and strong competition have reduced profits for most companies. 

A major factor affecting FMCG companies was the unexpected rise in palm oil prices, worsened by new government taxes on imported oils. Since companies didn’t have price protection (hedging) in place, their profit margins took a significant hit in the recent quarter. 

Potentials: 

Dabur India is growing its business while staying true to natural products. It is building new factories in South India and other places. Dabur also wants to make its factories eco-friendly by using less energy and water. The company is using new technology to make work faster and cheaper. 

Dabur is setting up a center to help its businesses worldwide. It is also working on sustainability by using more clean energy and cutting waste. The company is hiring more women and has started factories run by women. 

To meet demand, Dabur is making more products and selling more online. It is talking to customers through ads and promotions. 

Dabur is also adding new products to its brands. It has launched GlucoPlus-C Instant Energy Drink and entered the spices market with Badshah Masala. The company wants to grow bigger while caring for people and nature. 

Analyst Insights: 

  • Market capitalization:₹ 85,621 Cr. 
  • Current Price:₹ 483 
  • 52-Week High/Low: ₹ 672 / 480 
  • P/E Ratio:48.4 
  • Dividend Yield:1.12 % 
  • Return on Capital Employed (ROCE): 22.3 % 
  • Return on Equity (ROE): 19.2 % 

Dabur is a big company that makes good profits. It gives regular dividends to its investors. The company manages money well and earns good returns. It is also growing by making new products and expanding factories. 

However, there are some problems. Sales growth has been slow in the last five years, and the stock price is high compared to the company’s earnings. Right now, the stock is near its lowest price in a year, which shows that many investors are not confident. The FMCG sector is facing problems. Costs are going up, and fewer people are buying products.It is better to wait before buying this stock. If sales improve or the stock price becomes cheaper, it will be a better time to invest. 

Indrayani Biotech Ltd
Indrayani Biotech Q3 Results: Revenue Drops 55.79% YoY, Strong Stock Performance

Business and Industry Overview: 

Indrayani Biotech Limited (IBL) is a company with many businesses. It is managed by people who have over 20 years of experience. The company brings smaller businesses together to grow as one big organization. IBL works in different industries like food, hospitality, dairy, healthcare, pharma, engineering, biotech, agriculture, and infrastructure. These businesses were first run separately and later joined IBL after 2018. Some businesses were merged, and most became subsidiaries. Each business runs on its own, but IBL looks at the overall performance. IBL started on March 9, 1992, and became a public company on March 13, 1992. It first worked on growing roses, strawberries, tissue culture plants, and hybrid vegetable seeds. The company was listed on the BSE Stock Exchange on February 14, 1994. In 2019, IBL merged with A-Diet Hospitality Service Limited and Helios Solutions Limited. This was approved in 2020, and IBL started a healthcare business by forming IBL Healthcare Private Limited. In 2021, IBL restarted its biotech business and began making bio-fertilizers and pest controllers. It also bought Dindigul Farm Products Private Limited and Matrix Boilers Private Limited. Two more companies, IBL Investments Limited and IBL Social Foundation, were created. Between 2022 and 2023, IBL grew its healthcare sector by buying KNISS Laboratories Private Limited and taking a stake in Peekay Mediequip Limited. It also took control of Vaasan Medical Center. In 2024, Dindigul Farm Product Limited applied for an SME-IPO listing on BSE. IBL’s subsidiary HSL Agri Solution Limited also bought Dilasa Agro Processors Private Limited. IBL keeps growing by adding businesses with good potential and plans to expand further in different industries.  

Indrayani Biotech Limited (IBL) works in many fields like food, healthcare, farming, and engineering. It brings small businesses together to grow as one big company. This helps it get stronger in the market. The company has a team with many years of experience. It has also joined with other businesses to expand. IBL focuses on new technology and better ways to work. Since it is a public company, it gets money from investors to grow. Its many businesses and strong leadership help it stay competitive. 

Latest Stock News: 

Indrayani Biotech’s profit has dropped significantly in the December 2024 quarter. The company’s net profit fell by 75.51% to ₹0.24 crore, compared to ₹0.98 crore in the same quarter last year. Sales also declined sharply by 55.69%, from ₹39.09 crore in December 2023 to ₹17.32 crore in December 2024.  For the first nine months of the financial year, total sales decreased from ₹1,218.45 crore last year to ₹796.59 crore this year. Revenue also declined from ₹1,220.27 crore to ₹800.09 crore in the same period. Net income dropped from ₹62.42 crore to ₹24.19 crore. Earnings per share also fell from ₹0.86 last year to ₹0.1 this year, showing weaker profitability.   

The stock price has also been falling. Indrayani Biotech, which operates in the floriculture sector, has reached a new 52-week low. It has dropped 14.43% in the past five days and has fallen nearly 70% over the last year. The company’s stock is underperforming compared to the Sensex, showing investor concerns about its financial performance. 

Segmental information: 

Indrayani Biotech runs different types of businesses. It works in Food and Hospitality, Dairy, Healthcare & Pharma, Engineering, Biotech, Agriculture, and Infrastructure. These businesses were started by different people with years of experience. Later, they became part of Indrayani Biotech. 

  • Food and Hospitality: This business provides catering services and food-related solutions. 
  • Dairy: It collects, processes, and sells milk and dairy products. 
  • Healthcare & Pharma: It works in medicine, healthcare services, and biotech solutions. 
  • Engineering: This part of the company makes industrial and mechanical products. 
  • Biotech: It produces eco-friendly fertilizers and pest control products using microorganisms. 
  • Agriculture: It helps farmers by providing better farming products and services. 
  • Infrastructure: This business works on building projects and construction. 

Each of these businesses has its own team of experts. They make their own decisions but follow the company’s main rules. Indrayani Biotech looks at the overall results of all these businesses together. 

Subsidiary information:

Indrayani Biotech owns many smaller companies. These companies work in different industries but are part of Indrayani Biotech. Each company has its own team and handles its own business, but they all help Indrayani Biotech grow. 

List of Companies Under Indrayani Biotech: 

  1. IBL Healthcare Limited – Works in medicines and healthcare. It has also bought shares in other medical companies to expand. 
  1. IBL Investments Limited – Manages money and investments for Indrayani Biotech. 
  1. IBL Social Foundation – A charity organization that helps with education, healthcare, and community programs. 
  1. Dindigul Farm Products Limited – Works in food and farming. It became a public company in 2024 and plans to sell shares to the public soon.  
  1. HSL Agri Solutions Limited – Focuses on farming. It recently bought another company, Dilasa Agro Processors Private Limited, which processes food.  
  1. Matrix Boilers Private Limited – Makes boilers and other equipment for factories. 
  1. Healthway India Private Limited – Provides healthcare services and medical supplies. It is part of IBL Healthcare.
  1. KNISS Laboratories Private Limited – Makes medicines and other healthcare products. It is also part of IBL Healthcare.
  1. Peekay Mediequip Limited – Makes medical equipment. Indrayani Biotech owns a big part of this company.
  1. Vaasan Medical Center (India) Private Limited – A healthcare company that Indrayani Biotech took over to expand its business. 

Each of these companies focuses on a different business area. They work separately but help Indrayani Biotech grow in different industries. 

Q3 highlights: 

  • Q3 sales were ₹173.18 million, 56% lower than the same quarter last year (₹390.93 million). 
  • Q3 revenue was ₹173.22 million, 56% lower than last year (₹391.75 million). 
  • Q3 net income was ₹3.51 million, 68% lower than last year (₹10.82 million). 
  • Basic EPS for Q3 was ₹0.05, a drop from ₹0.22 last year. 
  • Diluted EPS for Q3 was ₹0.05, compared to ₹0.22 last year. 

Financial Summary:  

Amount in ₹ Cr Q3 FY24 Q3 FY25 FY23 FY24 
Revenue 30.81 17.32 163 165 
Expenses 26 14 145 142 
EBITDA 5 3 17.00 24.00 
OPM 18% 17% 11% 14% 
Other Income 0.09 0 4 1 
Net Profit 5.54 0.35 12 10 
NPM 17.98 2.02 7.36 6.06 
EPS 1.62 0.05 2.55 1.4 
Coal India Ltd
Coal India Ltd: Strong Potential, 30% Below ATH, Best Long-Term Picks

Business and Industry Overview

Coal India Limited (CIL) is the world’s largest coal producer. It was established in November 1975 & is classified as a ‘Maharatna’ enterprise under the Ministry of Coal, which means it has operational and financial autonomy. The company is headquartered in Kolkata and operates across eight Indian states. It has a total of 313 active mines, including 131 underground, 168 opencast, and 14 mixed mines. CIL has twelve subsidiaries and five joint venture companies that oversee the coal production across India.  

India aims to achieve a $5 trillion economy by 2025–26, with the coal sector playing a crucial role in ensuring energy security and driving economic growth, particularly in support of the thermal power sector. As the second-largest coal producer in the world, India produced 997.25 million tonnes (MT) of coal in 2023-24, reflecting an 11.65% increase. Coal India Limited contributed 773.647 MT, achieving a growth rate of 10.02%, while the Singareni Collieries Company Limited produced 70.02 MT, with a growth rate of 4.30%. Increased coal demand is anticipated from the electric vehicle sector and the chemicals industry as well. 

India may be pushing for a greener future, but coal still powers 72% of its electricity needs. As global narratives focus on renewables, coal is still responsible for 49% of India’s installed power capacity and generates over 70% of the country’s electricity. Coal India Limited (CIL) is the largest coal producer globally, supplying around 82% of India’s coal output and fulfilling 40% of energy needs. India is also working to minimise coal imports, with thermal coal imports decreasing by about 2% in 2024 due to enhanced domestic production and high inventory levels. Geopolitical factors are affecting global coal trade, with potential increases in U.S. coal exports to India. Despite ongoing efforts to diversify energy sources, coal continues to be a key component of India’s energy strategy, especially in the context of economic growth and environmental considerations. 

Latest Stock News

Southeastern Coalfields Limited (SECL), a subsidiary of Coal India Limited, has increased its budget for corporate social responsibility (CSR) activities, allocating ₹170 crore for the fiscal year 2025. This is an increase from the previous statutory budget of ₹99.76 crore. SECL operates 64 coal mines, with 39 located in Chhattisgarh and the remainder in Madhya Pradesh. The funding will primarily focus on improving health, education, and skill development in the region, with projects expected to be implemented over the next 2 to 3 years.  

Additionally, SECL signed a Memorandum of Understanding (MoU) worth ₹77 crore in 2025 for these initiatives. Among the notable projects is the provision of a 3.0 Tesla MRI machine for the Late Bisahu Das Mahant Memorial Medical College in Korba, which will cost approximately ₹28.08 crore. SECL is also earmarking ₹30.92 crore in financial assistance to the Vidisha district administration in Madhya Pradesh to address malnutrition and stunting, as well as screening for anemia and sickle cell anemia. 

In the October to December quarter of the financial year 2024-25, Coal India reported a net profit of ₹8,491.22 crore, reflecting a 17.5% decline compared to ₹10,291.71 crore in the same quarter the previous year. 

 On a sequential basis, the profit after tax (PAT) surged by 35% compared to the ₹6,289 crore reported in the second quarter of FY25. The company’s topline also increased by 17%, rising from ₹30,672 crore in the July-September quarter. 

On Monday, the state-run miner announced a 17% year-on-year decrease in its consolidated net profit for the December quarter, which stood at ₹8,506 crore compared to ₹10,253 crore in the same period last year. However, the profit after tax exceeded market expectations, which were estimated at ₹8,083 crore. 

Potentials

CIL’s coal production increased by 2% from last year to 543 million tonnes, but land issues and heavy rainfall affected growth. As a result, CIL has lowered its production target for FY25 to about 806 million tonnes, down from an earlier estimate of 838 million tonnes. Despite this, CIL aims to reach a target of 1,000 million tonnes by FY27, with a growth rate of about 6% annually to reach 925 million tonnes. 

CIL is also expanding its business beyond traditional coal mining. It is working on coal gasification projects with BHEL and GAIL, supported by about ₹1,350 crores in financial incentives for each project. CIL has signed an agreement with BPCL to create a coal-to-synthetic natural gas project and is investing in thermal power generation and renewable energy projects like Mahanadi Basin Power Ltd. Additionally, CIL is exploring opportunities to acquire and mine critical minerals in both domestic and international markets. These initiatives are expected to benefit CIL in the long run.The company is nearly debt-free.  

Coal India is anticipated to report a year-on-year (YoY) decline in its net profit for the quarter ending December 2024, primarily due to reduced realizations from weaker e-auction premiums. The board of directors will meet today, January 27, to review and approve the financial results for the third quarter of FY25.  

While a YoY drop in net profit is expected, there may be sequential growth compared to the previous quarter. Revenue for Q3 FY25 is projected to decrease YoY but increase sequentially. Flat volumes, lower blended realizations, and a slight rise in costs are expected to negatively impact operating profit.  

Additionally, Coal India’s board may consider declaring the second interim dividend for the fiscal year 2024-25. The record date for the dividend is set for January 27, 2025. Ahead of the Q3 results announcement, Coal India’s share price was trading down by one percent on Monday. 

Analyst Insights

The market capitalisation of Coal India Limited stands at ₹2,20,472 crore. The stock has a price-to-earnings (P/E) ratio of 6.34 and a book value of ₹156. Investors can expect a dividend yield of 7.19%. Additionally, the return on capital employed (ROCE) is an impressive 63.6%, while the return on equity (ROE) is 52.0%.The stock offers a solid dividend yield of 7.14%. The company has an impressive track record of return on equity (ROE), with a 3-Year ROE of 52.8%. Additionally, it has maintained a healthy dividend payout ratio of 49.8%. 

Coal India presents a strong investment opportunity with a dividend yield of 7.19%, making it attractive for income-focused investors. Its low P/E ratio of 6.34 suggests that the stock may be undervalued compared to its peers. The company’s high return on capital employed (ROCE) of 63.6% and return on equity (ROE) of 52.0% reflect efficient capital utilization and strong profitability. Additionally, Coal India has a consistent dividend payout ratio of 49.8%, providing stable returns for investors. 

However, there are potential risks to consider. Being a public sector unit (PSU), Coal India is dependent on government policies, which exposes it to regulatory risks. Furthermore, environmental concerns and the ongoing transition to renewable energy sources pose long-term risks for coal demand. The cyclical nature of commodities also means that prices and demand for coal can fluctuate significantly.  

In conclusion, the recommendation is to BUY if you are a dividend investor looking for stable cash flows and undervalued stocks. Alternatively, consider HOLDING if you already own the stock, as its fundamentals remain strong but long-term risks are present. 

Glenmark Pharma Ltd
Glenmark Pharma Q3 Results: Smart Recovery with ₹ 348 Crore Net Profit Driven by Higher Revenues

Business and Industry Overview: 

Glenmark Pharmaceuticals is a global research-driven pharmaceutical company. It was founded in 1977 by Gracias Saldanha as a company that makes generic drugs and active pharmaceutical ingredients. It is a research-focused global pharmaceutical company involved in branded, generic, and OTC products. The company focuses on Respiratory, Dermatology, and Oncology therapies. It has four research and development centres and ten top-quality manufacturing facilities on five continents, operating in over eighty countries. By using its strengths in innovation and research, the company aims to challenge traditional treatments and find new solutions that truly help patients around the world. By 2008, Glenmark was the fifth-largest pharmaceutical company in India.  

India is the largest global supplier of generic drugs and is well-known for its affordable vaccines and generic medications. The Indian pharmaceutical industry is currently ranked third in the world in terms of pharmaceutical production by volume. Over the past nine years, this sector has flourished, with a compound annual growth rate (CAGR) of 9.43%.  Key segments within the Indian pharmaceutical industry include generic drugs, over-the-counter medications, bulk drugs, vaccines, contract research and manufacturing, biosimilars, and biologics. India has the highest number of pharmaceutical manufacturing facilities that comply with the standards set by the U.S. Food and Drug Administration (USFDA).  Glenmark Pharmaceuticals is the e 14th largest and fastest growing pharmaceutical company in India and 15th largest generic company in the United States by prescriptions filled & 5th largest generic company in Europe.  

Latest Stock News: 

The company reported consolidated revenue of Rs. 33,876 million which is YoY growth of 35.1% for Q3FY25.  Its Europe Business YoY growth of 14.8% and  India Business at Rs. 10,637 million. The EBITDA of this quarter is at Rs. 6,002 million , with EBITDA margin of 17.7%  The PAT is at Rs. 3,480 Mn with a margin of 10.3%. Glenmark Pharmaceuticals announced the launch of Lacosamide Oral Solution, 10 mg/mL in December 2024. Lacosamide is a medication used to treat and prevent seizures, also known as convulsions, in individuals with epilepsy. This has helped the company with a surge in its price following its announcement in December 2024.  

Segmental information: 

  • Branded Generics: he company has a strong presence in emerging markets, concentrating on its core therapeutic areas. 
  • Dermatology: It is a market leader with the Candid anti-fungal range, which is a significant contributor to its success.  
  • Respiratory: The company is expanding its offerings in respiratory care by providing affordable inhalers and treatments. 
  • Oncology: There is a growing pipeline of cancer treatments designed to enhance its oncology portfolio. 
  • Consumer Healthcare: The company offers over-the-counter (OTC) products such as Scalpe+ anti-dandruff shampoo. 

Subsidiary Information:   

  • Glenmark Holding SA La Chaux-de-Fonds 
  • Glenmark Dominicana SRL 
  • Glenmark Pharmaceuticals Egypt S.A.E. 
  • Glenmark Pharmaceuticals Colombia SAS, Colombia 
  • Glenmark Pharmaceuticals FZE 
  • Glenmark Pharmaceuticals (Australia) Pty Ltd 
  • Glenmark Pharmaceuticals Kenya Ltd 
  • Glenmark Pharmaceuticals Malaysia Sdn Bhd 
  • Glenmark Pharmaceuticals B.V. 
  • Glenmark Pharmaceuticals Distribution s.r.o. 
  • Glenmark Pharmaceuticals Europe Ltd. 
  • Glenmark Pharmaceuticals (Europe) R&D Ltd. 
  • Glenmark Pharmaceuticals Singapore Pte. Ltd. 
  • Glenmark Pharmaceuticals S.R.O. 
  • Glenmark Philippines Inc. 
  • Glenmark Pharmaceuticals (Thailand) Co. Ltd. 
  • Glenmark Pharmaceuticals (Nigeria) Ltd 
  • Glenmark Pharmaceuticals Venezuela, C.A 
  • Glenmark South Africa Proprietary Limited 
  • Glenmark Pharmaceuticals South Africa Proprietary Limited 
  • Glenmark Life Sciences Limited 
  • Glenmark Arzneimittel GmbH 
  • Glenmark Farmaceutica Ltda 
  • GLENMARK PHARMACEUTICALS SP. Z O.O 
  • VISO Farmaceutica S.L.U 
  • Glenmark Pharmaceuticals SK SRO 
  • Glenmark Pharmaceuticals Inc. 
  • Glenmark Uruguay S.A. 
  • Glenmark Pharmaceuticals Canada Inc. 
  • Glenmark Pharmaceuticals Nordic AB 
  • Glenmark Ukraine LLC 

Q3 Highlights: 

  • Consolidated Revenue of Rs. 33,876 million with YoY growth of 35.1% 
  • Europe Business YoY growth of 14.8%  
  • India Business at Rs. 10,637 million 
  • EBITDA at Rs. 6,002 million, with EBITDA margin of 17.7%  
  • PAT at Rs. 3,480 million with a margin of 10.3% Other Highlights  
  • R&D Expenditure of Rs. 2,249 Mn (6.6% of revenue) 

Financial Summary: 

Amount in ₹ Cr Q3 FY24 Q3 FY25 FY23 FY24 
Revenue 2,507.00 3,388.00 11,583 11,813 
Expenses 2,715 2,787 9,948 10,618 
EBITDA -209 600 1,635.00 1,195.00 
OPM -8% 18% 14% 10% 
Other Income 87 31 -10 336 
Net Profit -331.00 348.00 377 -1,434 
NPM -13.20 10.27 3.25 -12.14 
EPS -12.45 12.33 24% -5% 
SJVN Ltd
SJVN Ltd Q3 Results: Net Profit Up 7%, Revenue Growth & Interim Dividend Declared

Business and Industry Overview: 

SJVN Limited is a Nava Ratna, Category-I, and Schedule ‘A’ Central Public Sector Enterprise (CPSE) under the Ministry of Power, Government of India, incorporated on May 24, 1988, as a joint venture between the Government of India and the Government of Himachal Pradesh. The company has a shareholder pattern of 64.46% from the Government of India, 25.51% from the Government of Himachal Pradesh, and 10.03% from the public, with a paid-up capital of Rs. 4,136.63 Crore and an authorized capital of Rs. 7,000 Crore. SJVN was conferred with Navratna status on August 30, 2024. Initially starting with the Nathpa Jhakri Hydro Power Station (1500 MW) in Himachal Pradesh, SJVN has since commissioned a total of 14 projects, amounting to 2467 MW of installed capacity. The company is currently implementing power projects across various states in India, including Himachal Pradesh, Uttarakhand, Bihar, Maharashtra, Uttar Pradesh, Punjab, Gujarat, Arunachal Pradesh, Rajasthan, Assam, Odisha, Mizoram, and Madhya Pradesh, as well as in Nepal. A significant milestone includes the commissioning of the 400 kV double circuit Indo-Nepal Cross Border Power Transmission corridor on February 19, 2016, along with ongoing work on a 217 km long transmission line from Arun-3 HEP to the Indo-Nepal border. 

Latest Stock News: 

SJVN Ltd, a hydropower public sector unit, reported a 7% increase in consolidated net profit, reaching Rs 148.75 crore for the December quarter. This rise is attributed to higher revenues, as the company posted a net profit of Rs 138.97 crore during the same period last year, according to a filing with the Bombay Stock Exchange (BSE).  

Total income for the quarter rose to Rs 760.76 crore, up from Rs 607.72 crore in the previous year.  

The board of directors has also approved an interim dividend of Rs 1.15 per equity share for the 2024-25 financial year. The record date for the interim dividend is February 21, 2025, and dividend payments will commence from March 6, 2025, onwards. 

Currently, the company’s shares are trading 2.60% lower at Rs 90.22, with a dividend yield of 1.99%. 

Segmental information:

1. Electricity Generation: 

Hydroelectric Power: SJVN’s core competency lies in hydroelectric power generation. The company operates significant projects, including the 1,500 MW Nathpa Jhakri Hydro Power Station and the 412 MW Rampur Hydro Power Station, both located in Himachal Pradesh. These facilities harness river water to produce renewable energy. citeturn0search12 

Wind Power: Expanding into wind energy, SJVN has commissioned projects like the 47.6 MW Khirvire Wind Power Project in Maharashtra and the 50 MW Sadla Wind Power Project in Gujarat. These installations utilize wind resources to generate electricity. citeturn0search0 

Solar Power: SJVN has ventured into solar energy with projects such as the 75 MW Parasan Solar Power Project in Uttar Pradesh and the 5.6 MW Charanka Solar Power Project in Gujarat. These solar installations contribute to the company’s renewable energy portfolio. citeturn0search12 

2. Consultancy Services: Leveraging its expertise in power generation, SJVN offers consultancy services encompassing project planning, feasibility studies, engineering, procurement, construction management, and operational support. These services cater to other entities in the power sector, facilitating the development of energy projects.  

3. Power Transmission: SJVN is involved in the transmission of electricity, ensuring efficient delivery from generation sites to distribution networks. This includes the construction, operation, and maintenance of transmission lines and substations, playing a crucial role in the power supply chain. citeturn0search1 

4. Power Trading:To optimize its energy portfolio, SJVN engages in power trading activities. This involves the buying and selling of electricity, allowing the company to respond to market dynamics, balance supply and demand, and enhance revenue generation. citeturn0search1 

5. Project Development and Execution: Beyond operating existing facilities, SJVN is actively involved in developing new power projects. This includes identifying potential sites, securing necessary approvals, and overseeing the construction and commissioning of new power plants across various energy sectors.  

Subsidiary Information:

SJVN Arun-3 Power Development Company Pvt. Ltd. (SAPDC) : A wholly owned subsidiary established in Nepal for the implementation of the 900 MW Arun-3 Project and its associated transmission system. 

SJVN Lower Arun Power Development Company Private Limited (SLPDC) : A fully owned subsidiary created for the development of the 669 MW Lower Arun Hydro Electric Project (HEP) in Nepal. 

 SJVN Thermal Private Limited (STPL) : A wholly owned subsidiary formed for the execution of the 1320 MW Buxar Thermal Power Project in Bihar. 

SJVN Green Energy Limited (SGEL) : A fully owned subsidiary established to focus on capacity additions in new and renewable energy sources. 

Joint Ventures  

Cross Border Power Transmission Company Limited (CPTC) : A joint venture among IEDCL, Power Grid, SJVN, and NEA with equity participation of 38%, 26%, 26%, and 10%, respectively. This venture aims to construct and maintain an 86 km long, 400 kV double circuit (D/C) transmission line from Sursund on the India-Nepal border to Muzaffarpur. 

Q3 Highlights:

  • SJVN Ltd Q3 results: Net profit rises by 7% to Rs 149 crore on higher revenue 
  • The board of directors has also approved an interim dividend of Rs 1.15 per equity share for 2024-25. 
  • SJVN Ltd Q3 results Net profit rises by 7 to Rs 149 crore on higher revenue 
  • The board of directors approved an interim dividend of Rs 1.15 per equity share for the 2024-25 financial year. 

Financial Summary:

Amount in ₹ Cr Q3 FY24 Q3 FY25 FY23 FY24 
Revenue 543.00 671.00 2,938 2,579 
Expenses 175 214 665 737 
EBITDA 368 457 2,273.00 1,843.00 
OPM 68% 68% 77% 71% 
Other Income 49 91 310 380 
Net Profit 139.00 149.00 1,359 911 
NPM 25.60 22.21 46.26 35.32 
EPS 0.35 0.38 3.46 2.32 
CRISIL Ltd
CRISIL Q3 Results: Net Profit Rises 7% to ₹225 Crore, Revenue Flat – Full Analysis

CRISIL Ltd: Business and Industry Overview 

CRISIL Ltd started in 1987, with collaboration between ICICI (Industrial Credit and Investment Corporation of India) and UTI (Unit Trust of India). CRISIL was the first credit rating agency in India. The operational segments of CRISIL are Research, Benchmarking, Consulting services and Analytics. It has expanded its footprint in multiple countries around the globe in USA, Europe, Middle East, Australia, and countries of Asia, serving many international big clients. CRISIL was later demerged from ICICI and was acquired by a US company S&P Global Ltd a credit scoring company. It has established really strong brands under its umbrella to expand in many service segments to become Ace. It started CRISIL Ratings, CRISIL Intelligence for market intelligence and analytics business segment, CRISIL Integral IQ and many more. It has total of 4600+ employees working over 12 countries. As this year’s government budget is more favoured towards consumption side, which will increase the money circulation in economy and will eventually result in higher inflation. CRISIL expects India’s GDP growth to be 6.5% for next fiscal year. It thinks bond issuances may experience tailwinds driven by easing in monetary policies. The industrial lending segment in short future will stay range bound but the personal lending portfolio of banks might see an increase.  

Latest Stock News 

Investors prefer the high quality of CRISL’s rating which has given CRISIL Ratings services a leading position in corporate bond segment. Research, Analytics and Solutions saw demand in buy-side offerings, consulting, and credit and risk offerings from global clients. In Q4 FY23, company saw gain of ₹29.4 crore due to sharp devaluation of Argentinian peso, and if we exclude that then PBT grew by 18.1% in this quarter YoY. Final dividend of ₹26 per share was declared, making the total dividend of ₹56 per share this year compared to ₹54 in FY23. It has recognized as a category leader in Chartis’ RiskTechCredit Portfolio Management (CPM) Solutions 2024 Quadrant, receiving 15 recognitions. To engage with clients it hosted 9th annual NBFC seminar in Mumbai, hosted conclave in real estate segment with title of ‘Shaping the Future of Real Estate’. CRISIL Coalition Greenwich hosted competitive challenges for asset managers in Chicago. CRISIL Integral IQ sponsored risk finance events focusing on trends in model risk, investment risk, impact of AI and technology, etc. During this quarter, CRISIL Foundation expanded its outreach and provided help to more than 4 lakh rural community members in Assam and Rajasthan under its flagship program ‘Mein Pragati’. 

Segment Information 

  • Ratings Services: This subsidiary provides ratings, which can help the issuers for funding and also for borrowers. Its services give an internal evaluation processes which includes screening of companies to ensure their operations and capabilities to repay or provide funding. Its services are majorly use in calculating the capital adequacy of banks. It has given rating to over 7000+ large and medium corporates and financial institutions. 
  • Research, Analytics and Solutions: It helps its clients with making strategic decisions, as it is expertise in collecting data and providing solutions to make companies grow their business and revenues. It has also worked with Indian Government as a support in making of PPP framework for India. Its services are offered in Asia, Africa and Middle East countries. It is the official rating provider of Indian Mutual Funds and a largest provider for fixed income valuations in India, covering more than ₹197 trillion. It also launched India’s first AIF benchmark to help AIF portfolios to compare their performance. 
  • International Business: It is a leading strategy implementation partner that works across globe helping companies in mitigating risks, make better decision, productive environment and enhance their returns. It serves 15 leading global investment bankers, 5 leading insurers, 40 credit risk teams of global banks.  

Subsidiaries Information 

  • CRISIL ESG Ratings & Analytics Ltd: This subsidiary provides ratings to companies and to banks globally for its credit lending or funding services helping them to optimize their capital. CRISIL ESG Ratings is registered with SEBI as a ‘Category 1’ ESG rating provider (ERP). It serves major banks, institutional and retail investors, asset managers, Mutual Funds and asset managers. 
  • Bridge to India Energy Private Limited: It is the leading consultancy and knowledge services provider in Indian renewable energy market. It provides wide range of services of consulting and research to contractors, companies, banks, government agencies, developers, financial institutions, etc. It is taking benefit of the comprehensive database it has to provide research and help their clients to grow and make the industry better. 
  • CRISIL Irevna Information Technology Columbia S.A.S: This subsidiary is based in Columbia, where many financial and technological professors work. It takes the outsourcing work of some key North American clients and helps them by providing research and strategic decision to grow their business. CRISIL has commenced a new unit in Columbia in Bogota to help them offer more services to their international clients. 
  • CRISIL Ratings Ltd: This subsidiary provides rating services to banks, financial institutions, mutual funds to rate their debt funding which will enhance the information making easy to invest or lend. Issuers and borrowers leverage its ratings to access funding, widening range of funding alternatives and optimize their capital. Government has made it compulsory for each mutual fund to have ratings, so that investors can make informed investments. 

Q3 FY25 Earnings 

  • Revenue of ₹913crore in Q3 FY25 down by 0.43% YoY from ₹917 crore in Q3 FY24.  
  • EBITDA of ₹317.7 crore in this quarter at a margin of 34.8% compared to 38.1% in Q3 FY24. 
  • Profit of ₹224.7 crore in this quarter compared to a ₹210 crore profit in Q3 FY24. 

Financial Summary 

Amount in ₹ Cr Q3 FY24 Q3 FY25 FY23 FY24 
Revenue 913 917 3139 3259 
Expenses 648.7 672.1 2365.5 2423 
EBITDA 317.7 349.4 975.1 1000 
OPM 34.8% 38.1% 31% 30.7% 
Other Income 30.2 33.2 93.6 89.6 
Net Profit 224.7 210.2 658 684 
NPM 24.6% 22.9% 20.9% 20.9% 
EPS 30.72 28.74 90.1 93.55 
GSK Pharma Ltd
GlaxoSmithKline Pharma Q3 Results: Strong Net Profit Soars 400% to ₹228.58 Cr, Revenue Up 18% YoY

Business and Industry Overview: 

GlaxoSmithKline Pharmaceuticals Limited (GSK Pharmaceuticals) is a leading research-based pharmaceutical and healthcare company in India, functioning as a subsidiary of the global entity GSK plc. Founded on November 13, 1924, originally as H.J. Foster & Co. Limited, the company has transformed over the decades into a significant player in India’s pharmaceutical sector. GSK is recognized as one of the top 10 drug manufacturers worldwide. In India, GSK’s operations include General Medicines, Pediatric Vaccines, and Adult Vaccines. The company’s Respiratory portfolio features products like Nucala and Trelegy, while its Adult Immunization category includes the Shingrix Herpes Zoster Vaccine. GSK is also implementing an omnichannel strategy to enhance its reach and service coverage. As of 2024, GSK’s net asset value was approximately 128 million Indian rupees. The company’s future performance may fluctuate due to various factors, including changes in industry trends, market conditions, government regulations, and other unforeseen circumstances. 

India is the largest global supplier of generic drugs and is well-known for its affordable vaccines and generic medications. The Indian pharmaceutical industry is currently ranked third in the world in terms of pharmaceutical production by volume. Over the past nine years, this sector has flourished, with a compound annual growth rate (CAGR) of 9.43%.  Key segments within the Indian pharmaceutical industry include generic drugs, over-the-counter medications, bulk drugs, vaccines, contract research and manufacturing, biosimilars, and biologics. India has the highest number of pharmaceutical manufacturing facilities that comply with the standards set by the U.S. Food and Drug Administration (USFDA). The country is home to numerous producers, which account for approximately 8% of the global active pharmaceutical ingredient (API) market. GSK is the leading player in this market, boasting a market share of 33%. 

Latest Stock News: 

GlaxoSmithKline (GSK) Pharmaceuticals announced an impressive 402% year-on-year (YoY) increase in consolidated net profit for the December quarter (Q3 FY25), reaching ₹228.58 crore, up from ₹45.49 crore in the same period last year. On February 14, GSK Pharmaceuticals reported an 18% revenue increase to ₹946 crore for the quarter ending December 31, 2024, along with a profit after tax of ₹229 crore. 

During this quarter, the company’s revenue from operations rose to ₹946.36 crore, reflecting a 17.5% YoY increase from ₹804.98 crore in Q3 FY24.  

However, compared to the previous quarter, the company experienced a decline: net profit fell by 8.08%, and revenue decreased by 5.4%, down from ₹248.68 crore and ₹1,000.05 crore reported in Q2 FY25, respectively. 

Segmental information:

Pharmaceuticals: GSK Pharmaceuticals offers a diverse range of prescription medicines across various therapeutic areas, including anti-infectives, dermatology, gynecology, diabetes, oncology, cardiovascular diseases, and respiratory ailments. 

Key Products: The company’s portfolio features leading brands such as Augmentin, a widely used antibiotic, and respiratory therapies like Nucala and Trelegy. These products have significantly contributed to the company’s growth, with Augmentin maintaining its position as the No.1 brand in the Indian pharmaceutical market.  

Pediatric Vaccines: GSK Pharmaceuticals provides vaccines aimed at preventing diseases such as hepatitis A and B, influenza, chickenpox, diphtheria, pertussis, tetanus, rotavirus, and cervical cancer. The pediatric vaccine portfolio has demonstrated double-digit growth, maintaining market leadership in the private sector. 

Adult Vaccines: The company is advancing adult immunization in India, notably with Shingrix, a vaccine for shingles. Innovative marketing strategies, including awareness campaigns featuring prominent figures, have bolstered the uptake of adult vaccines.  

Subsidiary Information:

ViiV Healthcare: Specializing in HIV treatment and prevention, ViiV Healthcare is a joint venture where GSK plc holds a majority stake of 76.5%, while Pfizer and Shionogi own 13.5% and 10%, respectively. This collaboration focuses on delivering advanced HIV therapies worldwide. 

Stiefel Laboratories: Acquired by GSK in 2009, Stiefel Laboratories specializes in dermatology products, thereby enhancing GSK’s portfolio in skin-related treatments. 

Reliant Pharmaceuticals: Purchased by GSK in 2007, Reliant Pharmaceuticals contributed a range of cardiovascular products, including Lovaza, an omega-3-acid ethyl ester, to GSK’s portfolio. 

Haleon: In July 2022, GSK plc demerged its consumer healthcare business to form Haleon, which focuses on over-the-counter products and wellness. This strategic move allowed GSK to concentrate more on its biopharmaceutical segments. 

Q3 Highlights:

  • GSK Pharmaceuticals reported a 402% YoY increase in net profit for Q3 FY25, totaling ₹228.58 crore (up from ₹45.49 crore last year).  
  • Revenue for the December 2024 quarter rose 18% to ₹946 crore. Revenue from operations increased by 17.5% YoY to ₹946.36 crore, compared to ₹804.98 crore in Q3 FY24.  
  • Compared to Q2 FY25, net profit fell by 8.08% and revenue decreased by 5.4% (down from ₹248.68 crore and ₹1,000.05 crore, respectively). 

Financial Summary:

Amount in ₹ Cr Q3 FY24 Q3 FY25 FY23 FY24 
Revenue 805.00 949.00 3,252 3,454 
Expenses 587 658 2,447 2,545 
EBITDA 218 292 804.00 909.00 
OPM 27% 31% 25% 26% 
Other Income -135 35 103 -21 
Net Profit 46.00 230.00 611 590 
NPM 5.71 24.24 18.79 17.08 
EPS 2.7 13.57 36.05 34.83 
Rail Vikas Nigam Ltd
Rail Vikas Nigam Ltd Q3 Results: Profit Down 13%, Revenue Slips 3%

Business and Industry Overview: 

Rail Vikas Nigam Limited (RVNL), a Central Public Sector Enterprise has been given the status of a Navratna PSU in India. It was established in 2003 under the Ministry of Railways. The organization aims to execute project development, financing, and implementation for all types of railway infrastructure. The primary focus of RVNL is to implement transportation infrastructure projects related to Indian Railways while mobilizing extra-budgetary resources through Special Purpose Vehicles (SPVs). Over its two decades of operation, RVNL has completed more than 150 railway projects. It has also expanded its focus to a broader range of infrastructure projects, both domestically and internationally. RVNL arranges financial resources, undertakes project execution, creates project-specific SPVs, and commercializes projects. After RVNL completes a railway project, the respective Zonal Railway operates and maintains it under specific financial arrangements. In the fiscal year 2021-22, RVNL successfully completed 18 projects, with a total of 102 projects completed since its inception up to March 2021. Currently, there are 72 projects at various stages of implementation by RVNL. The company is publicly traded on both the National Stock Exchange (NSE) and the Bombay Stock Exchange (BSE). 

As of March 31, 2023, the Indian railway network covers a route length of 68,584 kilometers (42,616 miles). The track sections are rated for speeds ranging from 80 to 200 kilometers per hour (50 to 124 miles per hour), with the maximum speed achieved by passenger trains being 160 kilometers per hour (99 miles per hour). Indian Railways, one of the largest railway networks managed under a single entity, transported approximately 19.8 million passengers and 2.4 million tonnes of freight each day in 2009, making it one of the world’s largest employers. The railways play a crucial role in transporting passengers and cargo across India’s vast territory, and RVNL is the only authority responsible for building and maintaining railway infrastructure. 

Latest Stock News: 

 On February 14, 2025, Rail Vikas Nigam’s stock price decreased by 2.19%, closing at ₹378.95 per share. The stock is currently trading at ₹370.65 per share. During the day, the stock reached a high of ₹387.40 and a low of ₹365.90. The company has a market capitalization of ₹78,992.43 crore, with a 52-week high of ₹647 and a low of ₹213. The BSE recorded a trading volume of 609,577 shares. 

RVNL on Friday (February 14) reported a 13.1% year-on-year (YoY) dip in net profit at ₹311.6 crore for the third quarter that ended December 31, 2024. In the same period in FY24, the company saw a net profit of ₹358.6 crore. 

At the operating level, EBITDA (earnings before interest, tax, depreciation, and amortisation) was down 3.9% YoY to ₹239.4 crore in Q3FY25 over ₹249 crore. The EBITDA margin was largely flat at 5.2% compared to 5.3% in the corresponding period in the previous fiscal. 

Segmental Information: 

New Lines/Doubling: The company has completed 1,343 km of project length, which includes 119 km of New Line, 925 km of Doubling, and 299 km of Railway Electrification, all of which have been handed over to the Zonal Railway. Additionally, it completed 863 km of the Metropolitan Transport Project. 

Railway Electrification: The company commissioned 299 route km (681 track km) of pure Railway Electrification works. 

Metro: RVNL commissioned the Joka-Taratala (13 km) section of Kolkata Metro and the New Garia-Hemanta Mukherjee (11 km) section of the New Garia-Biman Bandar Section. 

Subsidiary Information: 

High Speed Rail Corporation of India Limited: The High Speed Rail Corporation of India Limited (HSRC) is an SPV incorporated in 2012 as a subsidiary of RVNL to implement high-speed rail projects in India. 

Kinet Railway Solutions Ltd: RVNL has established a private company, Kinet Railway Solutions Ltd, which will act as the SPV signing the manufacturing-cum-maintenance agreement with the Ministry of Railways. 

Kyrgyzindustry-RVNL: RVNL also formed a 50:50 joint venture with the Kyrgyz company Kyrgyz Industry. This joint venture will develop rail, road, and other infrastructure in Kyrgyzstan.  

Q3 Highlights: 

  • Revenue went down to ₹4591 in Q3 FY25 from ₹4676 in the last quarter Q3 FY24.  
  • EBITDA was down 3.9% YoY to ₹239.4 crore in Q3FY25 over ₹249 crore.  
  • Shares of Rail Vikas Nigam Ltd ended at ₹360, down by ₹18.95, or 5%, on the BSE. 

Financial Summary: 

Amount in ₹ Cr Q3 FY24 Q3 FY25 FY23 FY24 
Revenue 4,676.00 4,591.00 20,282 21,733 
Expenses 4,676 4,328 20,282 21,733 
EBITDA 246 263 1,244.00 1,346.00 
OPM 5% 6% 6% 6% 
Other Income 326 284 1,004 1,183 
Net Profit 326.00 295.00 1,268 1,463 
NPM 6.97 6.43 6.25 6.73 
EPS 1.56 1.41 6.08 7.02 
Samvardhana Motherson
Samvardhana Motherson Q3 Results: 55.4% YoY Profit Surge to ₹984.35 Cr and Overview

Business and Industry Overview: 

Samvardhana Motherson is India’s leading auto parts manufacturer in terms of market capitalization, with notable clients including Maruti Suzuki and Mercedes-Benz. The company, officially known as Samvardhana Motherson International Ltd (formerly Motherson Sumi Systems Ltd), is a multinational manufacturer of automotive components headquartered in Noida, India. It specializes in producing wiring harnesses, plastic components, and rearview mirrors for passenger cars. Established in 1986, the company began as a joint venture with the Sumitomo Group of Japan. The Motherson Group provides a wide range of products and services through its 12 business divisions. With the support of its customers, these divisions continue to strengthen and diversify, helping Motherson move closer to its vision of becoming a globally preferred provider of sustainable solutions. The three key divisions of the group—Wiring Harness, Vision Systems and Modules, and Polymer Products—account for over 95% of the group’s revenues. Operating in 41 countries across North America, South America, Europe, South Africa, the Middle East, Asia-Pacific, and Australia, SAMIL manages more than 270 manufacturing facilities and employs over 135,000 professionals worldwide. This extensive global presence allows the company to effectively serve major automotive manufacturers, including Maruti Suzuki, Mercedes-Benz, Tata Motors, Volkswagen, Ford Motor Company, and Porsche. 

India’s auto parts industry is experiencing significant growth, with a projected value of $200 billion by 2026. This growth is driven by strong demand from both international markets and the local aftermarket, as well as original equipment sectors. In 2024, India produced 100,000 electric cars and 900,000 electric two-wheelers. However, Internal Combustion Engine (ICE) vehicles continue to dominate the market, with 20 million two-wheelers and 5 million cars still in circulation. The auto component industry plays a crucial role in India’s economy, contributing 2.3% to the GDP and employing over 1.5 million people. It is projected to grow to 5-7% of the GDP by 2026, which could create an additional 3.2 million jobs. Additionally, the industry is a leader in exports, with an estimated export value of $21.2 billion for 2023-24. Significant markets for these exports include North America, Europe, and Asia, with North America alone accounting for 32% of total exports and experiencing a 5% growth rate. Samvardhana Motherson India has a market share of more than 40% in the Indian wiring harness industry. 

Latest Stock News: 

Indian auto parts manufacturer Samvardhana Motherson reported a smaller-than-expected increase in its third-quarter profit on Friday, impacted by weak global car sales. For the quarter ending December 31, the company’s consolidated profit rose to Rs 8.79 billion ($101 million). However, this figure fell short of analysts’ estimates, which predicted a profit of Rs 9.4 billion, according to data compiled by LSEG. Quarterly revenue increased 8 percent.  

Segmental information: 

Wiring Harnesses: One of the major segments is Wiring Harnesses, which serve as the electrical distribution system for vehicles. These harnesses consist of a network of cables, connectors, and terminals that transmit power and signals between different electronic components. They are essential for various vehicle functions, including lighting, infotainment, engine control, and battery management in electric vehicles (EVs). 

Rearview Mirrors: Another important segment is Rearview Mirrors, which includes both exterior and interior mirrors equipped with advanced features. Modern rearview mirrors incorporate technologies such as electrochromic dimming (anti-glare), blind-spot detection, integrated cameras, and turn indicators. Samvardhana Motherson Reflectec (SMR), a subsidiary of SAMIL, is a global leader in automotive mirror systems. 

Moulded Plastic Parts: The Moulded Plastic Parts segment focuses on interior and exterior vehicle components made from plastic. These include dashboards, door trims, bumpers, center consoles, and air vents. Lightweight plastic components help improve fuel efficiency and reduce vehicle weight, which is especially important for EVs and modern fuel-efficient cars. SAMIL’s subsidiary, Samvardhana Motherson Peguform (SMP), specializes in these components, catering to global automakers. 

Rubber Components: The Rubber Components segment covers products such as seals, gaskets, and weatherstrips, which play a crucial role in noise reduction, vibration damping, and sealing gaps in vehicles. These components help prevent water leakage, reduce wind noise, and maintain cabin insulation, contributing to passenger comfort and vehicle durability. 

Modules and Systems: The Modules and Systems segment offers integrated solutions, including cockpit modules, complete door panels, instrument panels, and lighting systems. These pre-assembled units simplify installation for automakers and enhance production efficiency. The company’s expertise in module assembly and system integration makes it a valuable partner for major global auto manufacturers. 

Subsidiary Information:   

1. Samvardhana Motherson Reflectec (SMR : SMR is a leading global supplier specializing in rearview mirrors and camera-based detection systems. The subsidiary focuses on manufacturing exterior and interior mirrors equipped with advanced technologies, such as auto-dimming, integrated cameras, blind-spot detection, and turn indicators. These smart mirror solutions enhance driver safety and visibility, making them a critical component in modern vehicles. SMR serves major automakers worldwide, contributing significantly to SAMIL’s global revenues. 

2. Samvardhana Motherson Peguform (SMP) : SMP specializes in interior and exterior polymer modules, producing components such as dashboards, door panels, bumpers, and center consoles. These parts are essential for vehicle aesthetics, functionality, and structural integrity. SMP’s expertise in lightweight plastic components helps automakers improve fuel efficiency and reduce vehicle weight, aligning with the growing demand for electric and fuel-efficient vehicles. Through SMP, SAMIL has strengthened its position as a key supplier of high-quality plastic modules in the global automotive market. 

3. PKC Group : PKC Group is a Finnish company acquired by SAMIL in 2017, enhancing its expertise in wiring harnesses for commercial vehicles. Wiring harnesses are critical for electrical power distribution and signal transmission in automobiles, and PKC Group’s specialization extends beyond passenger cars to include trucks, buses, and heavy-duty commercial vehicles. This acquisition expanded SAMIL’s market reach into the commercial vehicle segment, allowing it to cater to a broader range of automotive manufacturers across the globe. 

Q3 Highlights: 

  • Total income for the quarter was ₹27,777 crore, representing an over 8% increase from ₹25,644 crore in the same period last year.  
  • Sequentially, profit rose nearly 4% from ₹949 crore in Q2FY25.  
  • Revenue declined marginally by 1% from ₹28,071 crore in Q2FY25. 
  • Samvardhana Motherson reported a net profit of ₹984.35 crore for Q3FY25, marking a 55.4% year-over-year increase.  

Financial Summary: 

Amount in ₹ Cr Q3 FY24 Q3 FY25 FY23 FY24 
Revenue 25,644.00 27,666.00 78,788 98,692 
Expenses 23,273 24,980 72,537 89,370 
EBITDA 2,370 2,686 6,251.00 9,322.00 
OPM 9% 10% 8% 9% 
Other Income 117 214 70 140 
Net Profit 633.00 984.00 1,670 3,020 
NPM 2.47 3.56 2.12 3.06 
EPS 2.7 13.57 29% 20% 
Hindalco
Hindalco Q3 Results: 60% Profit Surge to ₹3,735 Cr, Revenue at ₹58,899 Cr

Business and Industry Overview: 

Hindalco Industries is the metals flagship company of the Aditya Birla Group, valued at USD 28 billion, and is a leader in the aluminum and copper industries. In April 2020, the company strengthened its position as the world’s largest player in flat-rolled aluminum products by acquiring Aleris Corporation through its subsidiary, Novelis Inc. 

Hindalco operates a state-of-the-art copper facility, which features one of Asia’s largest custom copper smelters. In India, its aluminum operations encompass bauxite mining, alumina refining, copper production, and various downstream processes. The company ranks among the global aluminum majors and has a presence in nine countries. 

The Birla Copper unit is India’s largest private gold producer, manufacturing copper cathodes and various by-products. Hindalco holds Star Trading House status in India, and its aluminum and copper products are recognized on the London Metal Exchange. 

The aluminum industry in India is strategically positioned and is one of the largest producers globally, with clear growth plans and promising prospects for the future. India’s abundant bauxite mineral resources provide a competitive advantage to the industry compared to its global counterparts. As of September 2019, Hindalco’s domestic aluminum capacity was approximately 1.3 million tonnes, which accounted for nearly 40% of India’s total aluminum production. 

Latest Stock News: 

Hindalco Industries has reported a significant increase in its Q3 profits, with a 60% rise, bringing the net profit to Rs 3,735 crore for the December quarter. This is up from Rs 2,331 crore during the same period in the previous financial year (2023-24). The company’s total income also rose, reaching Rs 58,899 crore, compared to Rs 53,088 crore in the previous year.  

In addition to its strong financial performance, Hindalco announced the appointment of Bharat Goenka, currently the CFO-Designate, as the Chief Financial Officer, effective April 1, 2025. 

Due to ongoing geopolitical tensions and President Trump’s tariffs on imports, Satish Pai, Managing Director of Hindalco, said in an interview with Moneycontrol on February 14 that the company expects a neutral to positive impact on its US business. This follows the 25% tariff on all steel and aluminum imports into the United States. 

Segmental information: 

Hindlco has 2 major business segments. 

  1. Aluminum: In the Aluminium Business, Hindalco is a leading integrated producer with both upstream and downstream operations. Upstream operations include bauxite mining, which involves extracting raw materials; alumina refining, where bauxite is processed into alumina; and primary aluminum production, which smelts the alumina into ingots, billets, and wire rods. The downstream products consist of rolled products used in automotive, packaging, construction, and aerospace industries, extrusions for building and transportation, and foils and packaging products, including Freshwrapp and industrial foils. 
  1. Copper: In the Copper Business, Hindalco is India’s largest producer, operating an integrated smelting and refining facility. This segment focuses on producing copper cathodes for wiring and machinery, as well as continuous cast copper rods essential for power transmission. Additionally, valuable by-products such as sulfuric and phosphoric acids are produced for fertilizers and chemicals, along with gold and silver extracted during the smelting process. 

Subsidiary Information:  

  1. Utkal Alumina International Limited 
  1. Minerals & Minerals Limited 
  1. Suvas Holdings Limited. 
  1. Dahej Harbour & Infrastructure Limited 
  1. Hindalco Almex Aerospace Limited 
  1. East Coast Bauxite Mining Company Private Limited 
  1. Renuka Investments & Finance Limited 
  1. Renukeshwar Investments & Finance Limited 
  1. Lucknow Finance Company Limited 
  1. Utkal Alumina Social Welfare Foundation 
  1. Kosala Livelihood and Social Foundation 
  1. Birla Copper Asoj Private Limited 

Q3 Highlights: 

  •  Hindalco Industries reported a significant increase in Q3 profits, with a 60% rise. 
  • Net profit for the December quarter reached Rs 3,735 crore, up from Rs 2,331 crore in the same period of the previous financial year (2023-24). 
  • Total income rose to Rs 58,390 crore, compared to Rs 52,088 crore in the previous year. 
  •  Bharat Goenka, currently the CFO-Designate, has been appointed as the Chief Financial Officer, effective April 1, 2025. 

Financial Summary: 

Amount in ₹ Cr Q3 FY24 Q3 FY25 FY23 FY24 
Revenue 52,808.00 58,390.00 223,202 215,962 
Expenses 46,943.00 50,807 200,536 192,090 
EBITDA 5,865.00 7,583 22,666.00 23,872.00 
OPM 11% 13% 10% 11% 
Other Income 281 469 1,307 1,519 
Net Profit 2,331.00 3,735.00 10,097 10,155 
NPM 4.41 6.40  4.70 
EPS 10.37 16.62 44.93 45.19